Other Issues

The dietary supplement industry’s self-regulatory coalition, the SIDI Work Group, today released an updated draft of the “Standardized Information on Dietary Ingredients (SIDI) Protocol,” and seeks feedback from industry stakeholders and regulators by July 3, 2017.

A newly published article in the medical journal Pediatrics concludes that over-the-counter (OTC) cough and cold medicines for children are safe when used and stored as directed.

CHPA applauds CRN and UL for spearheading the Supplement OWL, which will prove to be a valuable resource for regulators, retailers and ultimately consumers.

“The results of this year’s Monitoring the Future survey demonstrate that prevention through education works,” Consumer Healthcare Products Association (CHPA) President and CEO Scott Melville said.

A recent study conducted by Charles River Associates, a leading global consulting firm, has quantified the savings consumers and the healthcare system receive from the over-the-counter (OTC) availability of the widely used cough suppressant dextromethorphan (DXM).

Substance Abuse Treatment, Prevention, and Policy recently published a case study authored by CHPA about the association’s efforts to curb teen abuse of OTC cough medicine containing dextromethorphan.

CHPA released the following statement today in support of a Delaware law prohibiting the sale of OTC medicines containing the cough suppressant dextromethorphan (DXM) to minors.

Unlike other drugs subject to user fees, nonprescription drugs under the Monograph system are not subject to FDA approval prior to marketing. Many of these ingredients have been marketed for more than 40 years, with a long history of safe use. We must define value differently than industries subject to FDA approval prior to marketing.